(Z)-Butylidenephthalide Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

188.2

<1mg/ml refers to the product slightly soluble or insoluble

C12H12O2

CCC/C=C(/c1c2cccc1)\OC2=O

72917-31-8

PKC

On the basis of in vitro release kinetics, we demonstrated that the (Z)-Butylidenephthalide-Wafer released 50% of the available (Z)-Butylidenephthalide by the sixth day, and the release reached a plateau phase (90% of (Z)-Butylidenephthalide) by the 30th day. To investigate the in situ antitumor effects of the Bdph-Wafer on glioblastoma multiforme (GBM), we used 2 xenograft animal models-F344 rats (for rat GBM) and nude mice (for human GBM)-which were injected with RG2 and DBTRG-05MG cells, respectively, for tumor formation and subsequently treated subcutaneously with (Z)-Butylidenephthalide-Wafers. We observed a significant inhibitory effect on tumor growth, with no significant adverse effects on the rodents. Moreover, we demonstrated that the antitumor effect of (Z)-Butylidenephthalide on RG2 cells was via the PKC pathway, which upregulated Nurr77 and promoted its translocation from the nucleus to the cytoplasm. Finally, to study the effect of the interstitial administration of z-butylidenephthalide in cranial brain tumor, Bdph-Wafers were surgically placed in FGF-SV40 transgenic mice. Our (Z)-Butylidenephthalide-Wafer significantly reduced tumor size in a dose-dependent manner.

Cytoskeletal Signaling; PKC